{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:27:33Z","timestamp":1794558453519,"version":"4.9.1"},"reference-count":135,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"USERN Foundation Houston TX USA","award":["2025.0717"],"award-info":[{"award-number":["2025.0717"]}]},{"name":"USERN Foundation Houston TX USA","award":["2025.0717"],"award-info":[{"award-number":["2025.0717"]}]},{"name":"USERN Foundation Houston TX USA","award":["2025.0717"],"award-info":[{"award-number":["2025.0717"]}]},{"name":"USERN Foundation Houston TX USA","award":["2025.0717"],"award-info":[{"award-number":["2025.0717"]}]},{"name":"USERN Foundation Houston TX USA","award":["2025.0717"],"award-info":[{"award-number":["2025.0717"]}]},{"name":"USERN Foundation Houston TX USA","award":["2025.0717"],"award-info":[{"award-number":["2025.0717"]}]},{"name":"USERN Foundation Houston TX USA","award":["2025.0717"],"award-info":[{"award-number":["2025.0717"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-025-02638-6","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T16:07:44Z","timestamp":1767629264000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Targeting T cell exhaustion in colorectal cancer: emerging roles of LAG-3, TIM-3, and TIGIT signaling in overcoming immunotherapy resistance"],"prefix":"10.1186","volume":"24","author":[{"given":"Pardis","family":"Zamani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erfan","family":"Barootchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayda","family":"Firouzabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam Sadat","family":"Tonekaboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiarash","family":"Saleki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloufar","family":"Yazdanpanah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"issue":"1","key":"2638_CR1","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1186\/s12885-025-15138-0","volume":"25","author":"S Wu","year":"2025","unstructured":"Wu S, Zhang Y, Lin Z, Wei M. Global burden of colorectal cancer in 2022 and projections to 2050: incidence and mortality estimates from GLOBOCAN. BMC Cancer. 2025;25(1):1770.","journal-title":"BMC Cancer"},{"issue":"8","key":"2638_CR2","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.3390\/cancers16081530","volume":"16","author":"G Roshandel","year":"2024","unstructured":"Roshandel G, Ghasemi-Kebria F, Malekzadeh R. Colorectal cancer: Epidemiology, risk Factors, and prevention. Cancers. 2024;16(8):1530.","journal-title":"Cancers"},{"issue":"3","key":"2638_CR3","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"2638_CR4","doi-asserted-by":"publisher","first-page":"v93","DOI":"10.1093\/annonc\/mdq222","volume":"21","author":"E Van Cutsem","year":"2010","unstructured":"Van Cutsem E, Nordlinger B, Cervantes A. Advanced colorectal cancer: ESMO clinical practice guidelines for treatment. Ann Oncol. 2010;21:v93\u20137.","journal-title":"Ann Oncol"},{"issue":"4","key":"2638_CR5","doi-asserted-by":"publisher","first-page":"495","DOI":"10.4240\/wjgs.v15.i4.495","volume":"15","author":"A Kumar","year":"2023","unstructured":"Kumar A, Gautam V, Sandhu A, Rawat K, Sharma A, Saha L. Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review. World J Gastrointest Surg. 2023;15(4):495\u2013519.","journal-title":"World J Gastrointest Surg"},{"key":"2638_CR6","doi-asserted-by":"crossref","unstructured":"Cervantes A, Adam R, Rosell\u00f3 S, Arnold D, Normanno N, Ta\u00efeb J, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up<\u2009sup>\u2606. Annals of Oncology. 2023;34(1):10\u201332.","DOI":"10.1016\/j.annonc.2022.10.003"},{"issue":"1","key":"2638_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13045-022-01294-4","volume":"15","author":"J Weng","year":"2022","unstructured":"Weng J, Li S, Zhu Z, Liu Q, Zhang R, Yang Y, et al. Exploring immunotherapy in colorectal cancer. J Hematol Oncol. 2022;15(1):95.","journal-title":"J Hematol Oncol"},{"issue":"14","key":"2638_CR8","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.7150\/ijbs.64077","volume":"17","author":"A Fan","year":"2021","unstructured":"Fan A, Wang B, Wang X, Nie Y, Fan D, Zhao X, et al. Immunotherapy in colorectal cancer: current achievements and future perspective. Int J Biol Sci. 2021;17(14):3837\u201349.","journal-title":"Int J Biol Sci"},{"issue":"2","key":"2638_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crin\u00f2 L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced Squamous-Cell Non-Small-Cell lung cancer. N Engl J Med. 2015;373(2):123\u201335.","journal-title":"N Engl J Med"},{"issue":"26","key":"2638_CR10","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C, Thomas L, Bondarenko I, O\u2019Day S, Weber J, Garbe C, et al. Ipilimumab plus Dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517\u201326.","journal-title":"N Engl J Med"},{"issue":"1","key":"2638_CR11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s10875-024-01810-w","volume":"45","author":"S Fekrvand","year":"2025","unstructured":"Fekrvand S, Abolhassani H, Esfahani ZH, Fard NNG, Amiri M, Salehi H, et al. Cancer trends in inborn errors of immunity: a systematic review and meta-analysis. J Clin Immunol. 2025;45(1):34.","journal-title":"J Clin Immunol"},{"key":"2638_CR12","first-page":"699","volume-title":"Volume 1: integration of psychology","author":"K Saleki","year":"2025","unstructured":"Saleki K, Rezaei N. Implication of T cell exhaustion in neuropsychiatric disorders: neuroimmunopathology and treatment strategies. Volume 1: integration of psychology. PsychoNeuroImmunology: Neurology, and Immunology: Springer; 2025. pp. 699\u2013719."},{"issue":"6","key":"2638_CR13","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.currproblcancer.2018.06.010","volume":"42","author":"R Gupta","year":"2018","unstructured":"Gupta R, Sinha S, Paul RN. The impact of microsatellite stability status in colorectal cancer. Curr Probl Cancer. 2018;42(6):548\u201359.","journal-title":"Curr Probl Cancer"},{"key":"2638_CR14","doi-asserted-by":"publisher","first-page":"118014","DOI":"10.1016\/j.biopha.2025.118014","volume":"186","author":"A Rahimi","year":"2025","unstructured":"Rahimi A, Baghernejadan Z, Hazrati A, Malekpour K, Samimi LN, Najafi A, et al. Combination therapy with immune checkpoint inhibitors in colorectal cancer: Challenges, resistance mechanisms, and the role of microbiota. Biomed Pharmacother. 2025;186:118014.","journal-title":"Biomed Pharmacother"},{"key":"2638_CR15","first-page":"1","volume":"42","author":"IH Sahin","year":"2022","unstructured":"Sahin IH, Ciombor KK, Diaz LA, Yu J, Kim R. Immunotherapy for microsatellite stable colorectal cancers: challenges and novel therapeutic avenues. Am Soc Clin Oncol Educ Book. 2022;42:1\u201312.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2638_CR16","doi-asserted-by":"crossref","unstructured":"Saleki K, Rezaei N. T-cell exhaustion in cancers. Cancer Immunology: The Immune System and Tumor. Publisher Springer Nature; 2025. p. 125\u201353.","DOI":"10.1007\/978-3-032-00749-0_9"},{"key":"2638_CR17","doi-asserted-by":"publisher","first-page":"114837","DOI":"10.1016\/j.intimp.2025.114837","volume":"159","author":"RK Sadegh","year":"2025","unstructured":"Sadegh RK, Saleki K, Rezaei N. Immune checkpoint inhibitor (ICI) therapy in central nervous system cancers: State-of-the-art and future outlook. Int Immunopharmacol. 2025;159:114837.","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"2638_CR18","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1084\/jem.188.12.2205","volume":"188","author":"AJ Zajac","year":"1998","unstructured":"Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman JD, et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med. 1998;188(12):2205\u201313.","journal-title":"J Exp Med"},{"issue":"10","key":"2638_CR19","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s00262-020-02593-w","volume":"69","author":"R Saleh","year":"2020","unstructured":"Saleh R, Taha RZ, Toor SM, Sasidharan Nair V, Murshed K, Khawar M, et al. Expression of immune checkpoints and T cell exhaustion markers in early and advanced stages of colorectal cancer. Cancer Immunol Immunother. 2020;69(10):1989\u201399.","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"2638_CR20","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","volume":"19","author":"A Chow","year":"2022","unstructured":"Chow A, Perica K, Klebanoff CA, Wolchok JD. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat Reviews Clin Oncol. 2022;19(12):775\u201390.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"4","key":"2638_CR21","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.it.2015.02.008","volume":"36","author":"KE Pauken","year":"2015","unstructured":"Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015;36(4):265\u201376.","journal-title":"Trends Immunol"},{"issue":"8","key":"2638_CR22","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486\u201399.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"2638_CR23","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","volume":"57","author":"N Joller","year":"2024","unstructured":"Joller N, Anderson AC, Kuchroo VK. LAG-3, TIM-3, and TIGIT: distinct functions in immune regulation. Immunity. 2024;57(2):206\u201322.","journal-title":"Immunity"},{"key":"2638_CR24","doi-asserted-by":"crossref","unstructured":"Chauvin JM, Zarour HM. TIGIT in cancer immunotherapy. J Immunother Cancer. 2020;8(2):e000957.","DOI":"10.1136\/jitc-2020-000957"},{"issue":"3","key":"2638_CR25","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/s41379-019-0322-9","volume":"33","author":"J Eug\u00e8ne","year":"2020","unstructured":"Eug\u00e8ne J, Jouand N, Ducoin K, Dansette D, Oger R, Deleine C, et al. The inhibitory receptor CD94\/NKG2A on CD8\u2009+\u2009tumor-infiltrating lymphocytes in colorectal cancer: a promising new druggable immune checkpoint in the context of HLAE\/\u03b22m overexpression. Mod Pathol. 2020;33(3):468\u201382.","journal-title":"Mod Pathol"},{"issue":"3","key":"2638_CR26","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s10120-020-01151-8","volume":"24","author":"K Mimura","year":"2021","unstructured":"Mimura K, Kua L-F, Xiao J-F, Asuncion BR, Nakayama Y, Syn N, et al. Combined Inhibition of PD-1\/PD-L1, Lag-3, and Tim-3 axes augments antitumor immunity in gastric cancer\u2013T cell coculture models. Gastric Cancer. 2021;24(3):611\u201323.","journal-title":"Gastric Cancer"},{"key":"2638_CR27","doi-asserted-by":"crossref","unstructured":"Tian T, Li Z. Targeting Tim-3 in cancer with resistance to PD-1\/PD-L1 blockade. Front Oncol. 2021;11:731175.","DOI":"10.3389\/fonc.2021.731175"},{"issue":"65, 1996","key":"2638_CR28","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1146\/annurev.bi.65.070196.000533","volume":"65","author":"P Modrich","year":"1996","unstructured":"Modrich P, Lahue R. MISMATCH REPAIR IN REPLICATION, FIDELITY, GENETIC RECOMBINATION, AND CANCER BIOLOGY. Annu Rev Biochem. 1996;65(65, 1996):101\u201333.","journal-title":"Annu Rev Biochem"},{"key":"2638_CR29","doi-asserted-by":"crossref","unstructured":"Kunkel TA, Erie DA. DNA MISMATCH REPAIR*. Annual Review of Biochemistry. 2005;74(Volume 74, 2005):681\u2013710.","DOI":"10.1146\/annurev.biochem.74.082803.133243"},{"issue":"6","key":"2638_CR30","doi-asserted-by":"publisher","first-page":"e28120","DOI":"10.1016\/j.heliyon.2024.e28120","volume":"10","author":"P Sun","year":"2024","unstructured":"Sun P, Luan Y, Cai X, Liu Q, Ren P, Xin P, et al. Predicting mechanism of immune response in microsatellite instability colorectal cancer. Heliyon. 2024;10(6):e28120.","journal-title":"Heliyon"},{"issue":"3","key":"2638_CR31","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s10689-016-9884-6","volume":"15","author":"Z Gatalica","year":"2016","unstructured":"Gatalica Z, Vranic S, Xiu J, Swensen J, Reddy S. High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine. Fam Cancer. 2016;15(3):405\u201312.","journal-title":"Fam Cancer"},{"issue":"5795","key":"2638_CR32","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1126\/science.1129139","volume":"313","author":"J Galon","year":"2006","unstructured":"Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pag\u00e8s C, et al. Type, Density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960\u20134.","journal-title":"Science"},{"key":"2638_CR33","doi-asserted-by":"publisher","first-page":"101461","DOI":"10.1016\/j.rechem.2024.101461","volume":"7","author":"R Shaikh","year":"2024","unstructured":"Shaikh R, Bhattacharya S, Prajapati BG. Microsatellite instability: A potential game-changer in colorectal cancer diagnosis and treatment. Results Chem. 2024;7:101461.","journal-title":"Results Chem"},{"key":"2638_CR34","first-page":"100746","volume":"36","author":"IA Voutsadakis","year":"2023","unstructured":"Voutsadakis IA. High tumor mutation burden (TMB) in microsatellite stable (MSS) colorectal cancers: diverse molecular associations point to variable pathophysiology. Cancer Treat Res Commun. 2023;36:100746.","journal-title":"Cancer Treat Res Commun"},{"issue":"3","key":"2638_CR35","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/bjc.2015.213","volume":"113","author":"L De Smedt","year":"2015","unstructured":"De Smedt L, Lemahieu J, Palmans S, Govaere O, Tousseyn T, Van Cutsem E, et al. Microsatellite instable vs stable colon carcinomas: analysis of tumour heterogeneity, inflammation and angiogenesis. Br J Cancer. 2015;113(3):500\u20139.","journal-title":"Br J Cancer"},{"key":"2638_CR36","doi-asserted-by":"crossref","unstructured":"Li J, Chen D, Shen M. Tumor microenvironment shapes colorectal cancer progression, metastasis, and treatment responses. Front Med. 2022;9:869010.","DOI":"10.3389\/fmed.2022.869010"},{"issue":"45","key":"2638_CR37","doi-asserted-by":"publisher","first-page":"5904","DOI":"10.1038\/onc.2008.271","volume":"27","author":"TL Whiteside","year":"2008","unstructured":"Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27(45):5904\u201312.","journal-title":"Oncogene"},{"key":"2638_CR38","doi-asserted-by":"publisher","first-page":"792691","DOI":"10.3389\/fimmu.2021.792691","volume":"12","author":"Y Chen","year":"2021","unstructured":"Chen Y, Zheng X, Wu C. The role of the tumor microenvironment and treatment strategies in colorectal cancer. Front Immunol. 2021;12:792691.","journal-title":"Front Immunol"},{"key":"2638_CR39","doi-asserted-by":"publisher","first-page":"149185","DOI":"10.1155\/2014\/149185","volume":"2014","author":"G Landskron","year":"2014","unstructured":"Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014;2014:149185.","journal-title":"J Immunol Res"},{"issue":"1","key":"2638_CR40","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12943-022-01616-7","volume":"21","author":"H Zhao","year":"2022","unstructured":"Zhao H, Ming T, Tang S, Ren S, Yang H, Liu M, et al. Wnt signaling in colorectal cancer: pathogenic role and therapeutic target. Mol Cancer. 2022;21(1):144.","journal-title":"Mol Cancer"},{"issue":"1","key":"2638_CR41","doi-asserted-by":"publisher","first-page":"15179","DOI":"10.1038\/srep15179","volume":"5","author":"B Shang","year":"2015","unstructured":"Shang B, Liu Y, Jiang S-j, Liu Y. Prognostic value of tumor-infiltrating FoxP3\u2009+\u2009regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep. 2015;5(1):15179.","journal-title":"Sci Rep"},{"issue":"3","key":"2638_CR42","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","volume":"37","author":"V Kumar","year":"2016","unstructured":"Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of Myeloid-Derived suppressor cells in the tumor microenvironment. Trends Immunol. 2016;37(3):208\u201320.","journal-title":"Trends Immunol"},{"issue":"11","key":"2638_CR43","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1038\/s12276-024-01340-w","volume":"56","author":"Z Ye","year":"2024","unstructured":"Ye Z, Li G, Lei J. Influencing immunity: role of extracellular vesicles in tumor immune checkpoint dynamics. Exp Mol Med. 2024;56(11):2365\u201381.","journal-title":"Exp Mol Med"},{"key":"2638_CR44","doi-asserted-by":"publisher","first-page":"982026","DOI":"10.3389\/fimmu.2022.982026","volume":"13","author":"L Yu","year":"2022","unstructured":"Yu L, Sun M, Zhang Q, Zhou Q, Wang Y. Harnessing the immune system by targeting immune checkpoints: providing new hope for oncotherapy. Front Immunol. 2022;13:982026.","journal-title":"Front Immunol"},{"issue":"4","key":"2638_CR45","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The Blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2638_CR46","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12935-024-03293-6","volume":"24","author":"A Zabeti Touchaei","year":"2024","unstructured":"Zabeti Touchaei A, Vahidi S. MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1\/PD-L1 and CTLA-4 pathways. Cancer Cell Int. 2024;24(1):102.","journal-title":"Cancer Cell Int"},{"issue":"6349","key":"2638_CR47","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 Blockade. Science. 2017;357(6349):409\u201313.","journal-title":"Science"},{"issue":"11","key":"2638_CR48","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/nm.3967","volume":"21","author":"J Guinney","year":"2015","unstructured":"Guinney J, Dienstmann R, Wang X, de Reyni\u00e8s A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350\u20136.","journal-title":"Nat Med"},{"issue":"10","key":"2638_CR49","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.3390\/cancers15102746","volume":"15","author":"L Rejali","year":"2023","unstructured":"Rejali L, Seifollahi Asl R, Sanjabi F, Fatemi N, Asadzadeh Aghdaei H, Saeedi Niasar M, et al. Principles of molecular utility for CMS classification in colorectal cancer management. Cancers. 2023;15(10):2746.","journal-title":"Cancers"},{"issue":"5","key":"2638_CR50","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1084\/jem.171.5.1393","volume":"171","author":"F Triebel","year":"1990","unstructured":"Triebel F, Jitsukawa S, Baixeras E, Roman-Roman S, Genevee C, Viegas-Pequignot E, et al. LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med. 1990;171(5):1393\u2013405.","journal-title":"J Exp Med"},{"issue":"5\u20136","key":"2638_CR51","doi-asserted-by":"publisher","first-page":"176","DOI":"10.18632\/genesandcancer.180","volume":"9","author":"L Long","year":"2018","unstructured":"Long L, Zhang X, Chen F, Pan Q, Phiphatwatchara P, Zeng Y, et al. The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy. Genes Cancer. 2018;9(5\u20136):176.","journal-title":"Genes Cancer"},{"issue":"10","key":"2638_CR52","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1002\/1521-4141(2001010)31:10<2885::AID-IMMU2885>3.0.CO;2-2","volume":"31","author":"N Iouzalen","year":"2001","unstructured":"Iouzalen N, Andreae S, Hannier S, Triebel F. LAP, a lymphocyte activation gene-3 (LAG\u20103)\u2010associated protein that binds to a repeated EP motif in the intracellular region of LAG\u20103, May participate in the down\u2010regulation of the CD3\/TCR activation pathway. Eur J Immunol. 2001;31(10):2885\u201391.","journal-title":"Eur J Immunol"},{"issue":"13","key":"2638_CR53","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1158\/0008-5472.CAN-13-2690","volume":"74","author":"F Xu","year":"2014","unstructured":"Xu F, Liu J, Liu D, Liu B, Wang M, Hu Z, et al. LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses. Cancer Res. 2014;74(13):3418\u201328.","journal-title":"Cancer Res"},{"issue":"4","key":"2638_CR54","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.bbagen.2005.12.020","volume":"1760","author":"J Dumic","year":"2006","unstructured":"Dumic J, Dabelic S, Fl\u00f6gel M. Galectin-3: an open-ended story. Biochim Et Biophys Acta (BBA)-General Subj. 2006;1760(4):616\u201335.","journal-title":"Biochim Et Biophys Acta (BBA)-General Subj"},{"key":"2638_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-021-01161-8","volume":"14","author":"W Qian","year":"2021","unstructured":"Qian W, Zhao M, Wang R, Li H. Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target. J Hematol Oncol. 2021;14:1\u201317.","journal-title":"J Hematol Oncol"},{"issue":"12","key":"2638_CR56","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1002\/(SICI)1521-4141(199912)29:12<3867::AID-IMMU3867>3.0.CO;2-E","volume":"29","author":"P Prigent","year":"1999","unstructured":"Prigent P, El mir S, Dr\u00e9ano M, Triebel F. Lymphocyte activation gene-3 induces tumor regression and antitumor immune responses. Eur J Immunol. 1999;29(12):3867\u201376.","journal-title":"Eur J Immunol"},{"issue":"9","key":"2638_CR57","doi-asserted-by":"publisher","first-page":"5916","DOI":"10.4049\/jimmunol.180.9.5916","volume":"180","author":"B Liang","year":"2008","unstructured":"Liang B, Workman C, Lee J, Chew C, Dale BM, Colonna L, et al. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol. 2008;180(9):5916\u201326.","journal-title":"J Immunol"},{"issue":"4","key":"2638_CR58","doi-asserted-by":"publisher","first-page":"324","DOI":"10.5114\/pjp.2021.114177","volume":"72","author":"J Xu","year":"2021","unstructured":"Xu J, Shen D, Zhang T, Wang J, De W, Zhang J. Lymphocyte-activated gene-3 (LAG3) protein expressed in tumor-infiltrating lymphocytes of colorectal cancer. Pol J Pathol. 2021;72(4):324\u201330.","journal-title":"Pol J Pathol"},{"issue":"12","key":"2638_CR59","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1038\/ni739","volume":"2","author":"JJ McIntire","year":"2001","unstructured":"McIntire JJ, Umetsu SE, Akbari O, Potter M, Kuchroo VK, Barsh GS, et al. Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family. Nat Immunol. 2001;2(12):1109\u201316.","journal-title":"Nat Immunol"},{"issue":"11","key":"2638_CR60","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/ni988","volume":"4","author":"CA Sabatos","year":"2003","unstructured":"Sabatos CA, Chakravarti S, Cha E, Schubart A, S\u00e1nchez-Fueyo A, Zheng XX, et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol. 2003;4(11):1102\u201310.","journal-title":"Nat Immunol"},{"issue":"8","key":"2638_CR61","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.molmed.2005.06.008","volume":"11","author":"JH Meyers","year":"2005","unstructured":"Meyers JH, Sabatos CA, Chakravarti S, Kuchroo VK. The TIM gene family regulates autoimmune and allergic diseases. Trends Mol Med. 2005;11(8):362\u20139.","journal-title":"Trends Mol Med"},{"issue":"3","key":"2638_CR62","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.4049\/jimmunol.176.3.1411","volume":"176","author":"H Geng","year":"2006","unstructured":"Geng H, Zhang G-M, Li D, Zhang H, Yuan Y, Zhu H-G, et al. Soluble form of T cell Ig mucin 3 is an inhibitory molecule in T cell-mediated immune response. J Immunol. 2006;176(3):1411\u201320.","journal-title":"J Immunol"},{"issue":"5853","key":"2638_CR63","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1126\/science.1148536","volume":"318","author":"AC Anderson","year":"2007","unstructured":"Anderson AC, Anderson DE, Bregoli L, Hastings WD, Kassam N, Lei C, et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science. 2007;318(5853):1141\u20133.","journal-title":"Science"},{"issue":"4","key":"2638_CR64","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.4049\/jimmunol.1400557","volume":"193","author":"RL Ferris","year":"2014","unstructured":"Ferris RL, Lu B, Kane LP. Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion. J Immunol. 2014;193(4):1525\u201330.","journal-title":"J Immunol"},{"issue":"9","key":"2638_CR65","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/nm.2871","volume":"18","author":"M Rangachari","year":"2012","unstructured":"Rangachari M, Zhu C, Sakuishi K, Xiao S, Karman J, Chen A, et al. Bat3 promotes T cell responses and autoimmunity by repressing Tim-3\u2013mediated cell death and exhaustion. Nat Med. 2012;18(9):1394\u2013400.","journal-title":"Nat Med"},{"key":"2638_CR66","doi-asserted-by":"crossref","unstructured":"Qin S, Dong B, Yi M, Chu Q, Wu K. Prognostic values of TIM-3 expression in patients with solid tumors: a meta-analysis and database evaluation. Front Oncol. 2020;10:1288.","DOI":"10.3389\/fonc.2020.01288"},{"key":"2638_CR67","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1007\/s00262-021-02886-8","volume":"70","author":"R Liang","year":"2021","unstructured":"Liang R, Zhu X, Lan T, Ding D, Zheng Z, Chen T, et al. TIGIT promotes CD8\u2009+\u2009T cells exhaustion and predicts poor prognosis of colorectal cancer. Cancer Immunol Immunother. 2021;70:2781\u201393.","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"2638_CR68","first-page":"8018","volume":"8","author":"E Zhou","year":"2015","unstructured":"Zhou E, Huang Q, Wang J, Fang C, Yang L, Zhu M, et al. Up-regulation of Tim-3 is associated with poor prognosis of patients with colon cancer. Int J Clin Exp Pathol. 2015;8(7):8018.","journal-title":"Int J Clin Exp Pathol"},{"issue":"4","key":"2638_CR69","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/sj.jid.5700616","volume":"127","author":"Z Wiener","year":"2007","unstructured":"Wiener Z, Kohalmi B, Pocza P, Jeager J, Tolgyesi G, Toth S, et al. TIM-3 is expressed in melanoma cells and is upregulated in TGF-beta stimulated mast cells. J Invest Dermatology. 2007;127(4):906\u201314.","journal-title":"J Invest Dermatology"},{"issue":"6","key":"2638_CR70","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.3390\/cancers15061697","volume":"15","author":"G Cazzato","year":"2023","unstructured":"Cazzato G, Cascardi E, Colagrande A, Lettini T, Filosa A, Arezzo F, et al. T cell Immunoglobulin and mucin domain 3 (TIM-3) in cutaneous melanoma: a narrative review. Cancers. 2023;15(6):1697.","journal-title":"Cancers"},{"issue":"2","key":"2638_CR71","doi-asserted-by":"publisher","first-page":"490","DOI":"10.3892\/ol.2013.1410","volume":"6","author":"Y Shang","year":"2013","unstructured":"Shang Y, Li Z, Li H, Xia H, Lin Z. TIM-3 expression in human osteosarcoma: correlation with the expression of epithelial\u2013mesenchymal transition-specific biomarkers. Oncol Lett. 2013;6(2):490\u20134.","journal-title":"Oncol Lett"},{"issue":"6","key":"2638_CR72","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.7314\/APJCP.2013.14.6.3897","volume":"14","author":"Y-R Piao","year":"2013","unstructured":"Piao Y-R, Piao L-Z, Zhu L-H, Jin Z-H, Dong X-Z. Prognostic value of T cell Immunoglobulin mucin-3 in prostate cancer. Asian Pac J Cancer Prev. 2013;14(6):3897\u2013901.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"6","key":"2638_CR73","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1309\/AJCP9Q6OVLVSHTMY","volume":"137","author":"X Zhuang","year":"2012","unstructured":"Zhuang X, Zhang X, Xia X, Zhang C, Liang X, Gao L, et al. Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC. Am J Clin Pathol. 2012;137(6):978\u201385.","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"2638_CR74","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.stem.2010.11.014","volume":"7","author":"Y Kikushige","year":"2010","unstructured":"Kikushige Y, Shima T, Takayanagi S-i, Urata S, Miyamoto T, Iwasaki H, et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell. 2010;7(6):708\u201317.","journal-title":"Cell Stem Cell"},{"issue":"5","key":"2638_CR75","first-page":"5899","volume":"14","author":"H Lin","year":"2017","unstructured":"Lin H, Yang B, Teng M. T\u2013cell Immunoglobulin mucin\u20133 as a potential inducer of the epithelial\u2013mesenchymal transition in hepatocellular carcinoma. Oncol Lett. 2017;14(5):5899\u2013905.","journal-title":"Oncol Lett"},{"issue":"9","key":"2638_CR76","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/ni.2376","volume":"13","author":"S Chiba","year":"2012","unstructured":"Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H, et al. Tumor-infiltrating DCs suppress nucleic acid\u2013mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol. 2012;13(9):832\u201342.","journal-title":"Nat Immunol"},{"issue":"1","key":"2638_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/08820139.2022.2113407","volume":"52","author":"Q Shi","year":"2023","unstructured":"Shi Q, Li G, Dou S, Tang L, Hou C, Wang Z, et al. Negative regulation of RIG-I by Tim-3 promotes H1N1 infection. Immunol Investig. 2023;52(1):1\u201319.","journal-title":"Immunol Investig"},{"issue":"1","key":"2638_CR78","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13045-023-01405-9","volume":"16","author":"Y Jiang","year":"2023","unstructured":"Jiang Y, Zhang H, Wang J, Chen J, Guo Z, Liu Y, et al. Exploiting RIG-I-like receptor pathway for cancer immunotherapy. J Hematol Oncol. 2023;16(1):8.","journal-title":"J Hematol Oncol"},{"key":"2638_CR79","doi-asserted-by":"publisher","unstructured":"Ma B, Akosman B, Kamle S, Lee C-M, He CH, Koo JS, et al. CHI3L1 regulates PD-L1 and anti\u2013CHI3L1\u2013PD-1 antibody elicits synergistic antitumor responses. J Clin Investig. 2021;131(21):e137750. https:\/\/doi.org\/10.1172\/JCI137750.","DOI":"10.1172\/JCI137750"},{"issue":"24","key":"2638_CR80","doi-asserted-by":"publisher","first-page":"20592","DOI":"10.18632\/oncotarget.4112","volume":"6","author":"B Xu","year":"2015","unstructured":"Xu B, Yuan L, Gao Q, Yuan P, Zhao P, Yuan H, et al. Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer. Oncotarget. 2015;6(24):20592\u2013603.","journal-title":"Oncotarget"},{"issue":"1","key":"2638_CR81","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/ni.1674","volume":"10","author":"X Yu","year":"2009","unstructured":"Yu X, Harden K, Gonzalez C, Francesco L, Chiang M, Irving E. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009;10(1):48\u201357.","journal-title":"Nat Immunol"},{"issue":"8","key":"2638_CR82","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1002\/eji.201243072","volume":"43","author":"N Stanietsky","year":"2013","unstructured":"Stanietsky N, Rovis TL, Glasner A, Seidel E, Tsukerman P, Yamin R, et al. Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR. Eur J Immunol. 2013;43(8):2138\u201350.","journal-title":"Eur J Immunol"},{"key":"2638_CR83","doi-asserted-by":"publisher","first-page":"699895","DOI":"10.3389\/fimmu.2021.699895","volume":"12","author":"Z Ge","year":"2021","unstructured":"Ge Z, Peppelenbosch MP, Sprengers D, Kwekkeboom J. TIGIT, the next step towards successful combination immune checkpoint therapy in cancer. Front Immunol. 2021;12:699895.","journal-title":"Front Immunol"},{"issue":"1","key":"2638_CR84","doi-asserted-by":"publisher","first-page":"e000266","DOI":"10.1136\/jitc-2019-000266","volume":"8","author":"A Reches","year":"2020","unstructured":"Reches A, Ophir Y, Stein N, Kol I, Isaacson B, Amikam YC, et al. Nectin4 is a novel TIGIT ligand which combines checkpoint Inhibition and tumor specificity. J Immunother Cancer. 2020;8(1):e000266.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"2638_CR85","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.immuni.2015.01.010","volume":"42","author":"C Gur","year":"2015","unstructured":"Gur C, Ibrahim Y, Isaacson B, Yamin R, Abed J, Gamliel M, et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity. 2015;42(2):344\u201355.","journal-title":"Immunity"},{"issue":"6","key":"2638_CR86","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","volume":"26","author":"RJ Johnston","year":"2014","unstructured":"Johnston RJ, Comps-Agrar L, Hackney J, Yu X, Huseni M, Yang Y, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8\u2009+\u2009T cell effector function. Cancer Cell. 2014;26(6):923\u201337.","journal-title":"Cancer Cell"},{"key":"2638_CR87","doi-asserted-by":"publisher","unstructured":"Wang CQ, Choy FC, Sanny A, Murakami T, Tan AH, Lam KP. An inhibitory role for human CD96 endodomain in T cell Anti-Tumor responses. Cells. 2023;12(2):309. https:\/\/doi.org\/10.3390\/cells12020309.","DOI":"10.3390\/cells12020309"},{"issue":"4","key":"2638_CR88","doi-asserted-by":"publisher","first-page":"101012","DOI":"10.1016\/j.xcrm.2023.101012","volume":"4","author":"S Ohtsuki","year":"2023","unstructured":"Ohtsuki S, Wang C, Watanabe R, Zhang H, Akiyama M, Bois MC, et al. Deficiency of the CD155-CD96 immune checkpoint controls IL-9 production in giant cell arteritis. Cell Rep Med. 2023;4(4):101012.","journal-title":"Cell Rep Med"},{"issue":"6","key":"2638_CR89","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/eji.201948405","volume":"50","author":"EY Chiang","year":"2020","unstructured":"Chiang EY, de Almeida PE, de Almeida Nagata DE, Bowles KH, Du X, Chitre AS, et al. CD96 functions as a co-stimulatory receptor to enhance CD8(+) T cell activation and effector responses. Eur J Immunol. 2020;50(6):891\u2013902.","journal-title":"Eur J Immunol"},{"issue":"2","key":"2638_CR90","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s10238-022-00817-0","volume":"23","author":"D Qiu","year":"2023","unstructured":"Qiu D, Liu X, Wang W, Jiang X, Wu X, Zheng J, et al. TIGIT axis: novel immune checkpoints in anti-leukemia immunity. Clin Experimental Med. 2023;23(2):165\u201374.","journal-title":"Clin Experimental Med"},{"key":"2638_CR91","doi-asserted-by":"crossref","unstructured":"Houssaini MS, Damou M, Ismaili N. Advances in the management of non-small cell lung cancer (NSCLC): a new practice changing data from asco 2020 annual meeting. Cancer treatment and research communications. 2020;25:100239.","DOI":"10.1016\/j.ctarc.2020.100239"},{"issue":"21","key":"2638_CR92","doi-asserted-by":"publisher","first-page":"8086","DOI":"10.1002\/cam4.3410","volume":"9","author":"Z Wang","year":"2020","unstructured":"Wang Z, Wu X. Study and analysis of antitumor resistance mechanism of PD1\/PD-L1 immune checkpoint blocker. Cancer Med. 2020;9(21):8086\u2013121.","journal-title":"Cancer Med"},{"key":"2638_CR93","doi-asserted-by":"publisher","first-page":"831407","DOI":"10.3389\/fonc.2022.831407","volume":"12","author":"Y Wei","year":"2022","unstructured":"Wei Y, Li Z. LAG3-PD-1 combo overcome the disadvantage of drug resistance. Front Oncol. 2022;12:831407.","journal-title":"Front Oncol"},{"key":"2638_CR94","doi-asserted-by":"crossref","unstructured":"Andrews LP, Somasundaram A, Moskovitz JM, et al. Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding. Sci Immunol. 2020;5(49):eabc2728.","DOI":"10.1126\/sciimmunol.abc2728"},{"issue":"4","key":"2638_CR95","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","volume":"72","author":"SR Woo","year":"2012","unstructured":"Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012;72(4):917\u201327.","journal-title":"Cancer Res"},{"issue":"6","key":"2638_CR96","doi-asserted-by":"publisher","first-page":"100639","DOI":"10.1016\/j.esmoop.2022.100639","volume":"7","author":"E Garralda","year":"2022","unstructured":"Garralda E, Sukari A, Lakhani NJ, Patnaik A, Lou Y, Im SA, et al. A first-in-human study of the anti-LAG-3 antibody Favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer. ESMO Open. 2022;7(6):100639.","journal-title":"ESMO Open"},{"key":"2638_CR97","doi-asserted-by":"crossref","unstructured":"Overman MJ, et al. Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II checkmate 142 study. J Immunother Cancer. 2024;12(5):e008689.","DOI":"10.1136\/jitc-2023-008689"},{"issue":"10","key":"2638_CR98","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1007\/s00262-022-03182-9","volume":"71","author":"M Thibaudin","year":"2022","unstructured":"Thibaudin M, Limagne E, Hampe L, Ballot E, Truntzer C, Ghiringhelli F. Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer. Cancer Immunol Immunother. 2022;71(10):2549\u201363.","journal-title":"Cancer Immunol Immunother"},{"issue":"16Supplement","key":"2638_CR99","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1158\/1538-7445.AM2020-779","volume":"80","author":"J Bendell","year":"2020","unstructured":"Bendell J, Ulahannan SV, Chu Q, Patel M, George B, Auguste A, et al. A phase I study of BI 754111, an anti-LAG-3 monoclonal antibody (mAb), in combination with BI 754091, an anti-PD-1 mAb: biomarker analyses from the microsatellite stable metastatic colorectal cancer (MSS mCRC) cohort. Cancer Res. 2020;80(16Supplement):779.","journal-title":"Cancer Res"},{"key":"2638_CR100","doi-asserted-by":"crossref","unstructured":"Garralda E, Sukari A, Lakhani NJ, Patnaik A, Lou Y, Im S-A, et al. A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer. J Clin Oncol. 2021;39:3584.","DOI":"10.1200\/JCO.2021.39.15_suppl.3584"},{"key":"2638_CR101","doi-asserted-by":"publisher","first-page":"S376","DOI":"10.1016\/j.annonc.2022.04.453","volume":"33","author":"A Bullock","year":"2022","unstructured":"Bullock A, Grossman J, Fakih M, Lenz H, Gordon M, Margolin K, et al. LBA O-9 Botensilimab, a novel innate\/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer. Ann Oncol. 2022;33:S376.","journal-title":"Ann Oncol"},{"issue":"8","key":"2638_CR102","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","volume":"36","author":"MJ Overman","year":"2018","unstructured":"Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch Repair-Deficient\/Microsatellite Instability-High metastatic colorectal cancer. J Clin Oncol. 2018;36(8):773\u20139.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2638_CR103","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1001\/jamaoncol.2020.0910","volume":"6","author":"EX Chen","year":"2020","unstructured":"Chen EX, Jonker DJ, Loree JM, Kennecke HF, Berry SR, Couture F, et al. Effect of combined immune checkpoint Inhibition vs best supportive care alone in patients with advanced colorectal cancer: the Canadian cancer trials group CO. 26 study. JAMA Oncol. 2020;6(6):831\u20138.","journal-title":"JAMA Oncol"},{"key":"2638_CR104","first-page":"112","volume":"15","author":"S Kamatham","year":"2019","unstructured":"Kamatham S, Shahjehan F, Kasi PM. Immune checkpoint inhibitors in metastatic colorectal cancer: current status, recent advances, and future directions. Curr Colorectal Cancer Rep. 2019;15:112\u201321.","journal-title":"Curr Colorectal Cancer Rep"},{"issue":"9","key":"2638_CR105","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.neo.2019.07.006","volume":"21","author":"E Fiegle","year":"2019","unstructured":"Fiegle E, Doleschel D, Koletnik S, Rix A, Weiskirchen R, Borkham-Kamphorst E, et al. Dual CTLA-4 and PD-L1 Blockade inhibits tumor growth and liver metastasis in a highly aggressive orthotopic mouse model of colon cancer. Neoplasia. 2019;21(9):932\u201344.","journal-title":"Neoplasia"},{"key":"2638_CR106","doi-asserted-by":"publisher","first-page":"108429","DOI":"10.1016\/j.clim.2020.108429","volume":"215","author":"S Khalaf","year":"2020","unstructured":"Khalaf S, Toor SM, Murshed K, Kurer MA, Ahmed AA, Abu Nada M, et al. Differential expression of TIM-3 in circulation and tumor microenvironment of colorectal cancer patients. Clin Immunol. 2020;215:108429.","journal-title":"Clin Immunol"},{"issue":"12","key":"2638_CR107","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1080\/14728222.2024.2442437","volume":"28","author":"R Karami","year":"2024","unstructured":"Karami R, Fathi M, Jalali P, Hassannia H, Zarei A, Hojjat-Farsangi M, et al. The emerging role of TIM-3 in colorectal cancer: a promising target for immunotherapy. Expert Opin Ther Targets. 2024;28(12):1093\u2013115.","journal-title":"Expert Opin Ther Targets"},{"key":"2638_CR108","doi-asserted-by":"publisher","first-page":"1069696","DOI":"10.3389\/fonc.2023.1069696","volume":"13","author":"Z Mokhtari","year":"2023","unstructured":"Mokhtari Z, Rezaei M, Sanei MH, Dehghanian A, Faghih Z, Heidari Z, et al. Tim3 and PD-1 as a therapeutic and prognostic targets in colorectal cancer: relationship with sidedness, clinicopathological parameters, and survival. Front Oncol. 2023;13:1069696.","journal-title":"Front Oncol"},{"issue":"1","key":"2638_CR109","first-page":"5440572","volume":"2021","author":"K Xiao","year":"2021","unstructured":"Xiao K, Xiao K, Li K, Xue P, Zhu S. Prognostic role of TIGIT expression in patients with solid tumors: a meta-analysis. J Immunol Res. 2021;2021(1):5440572.","journal-title":"J Immunol Res"},{"issue":"3","key":"2638_CR110","doi-asserted-by":"publisher","first-page":"e0265908","DOI":"10.1371\/journal.pone.0265908","volume":"17","author":"D Murakami","year":"2022","unstructured":"Murakami D, Matsuda K, Iwamoto H, Mitani Y, Mizumoto Y, Nakamura Y, et al. Prognostic value of CD155\/TIGIT expression in patients with colorectal cancer. PLoS ONE. 2022;17(3):e0265908.","journal-title":"PLoS ONE"},{"issue":"17","key":"2638_CR111","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.3390\/cancers14174261","volume":"14","author":"K Ducoin","year":"2022","unstructured":"Ducoin K, Bilonda-Mutala L, Deleine C, Oger R, Duchalais E, Jouand N, et al. Defining the immune checkpoint landscape in human colorectal cancer highlights the relevance of the TIGIT\/CD155 axis for optimizing immunotherapy. Cancers. 2022;14(17):4261.","journal-title":"Cancers"},{"key":"2638_CR112","doi-asserted-by":"publisher","first-page":"688961","DOI":"10.3389\/fimmu.2021.688961","volume":"12","author":"Q Shao","year":"2021","unstructured":"Shao Q, Wang L, Yuan M, Jin X, Chen Z, Wu C. TIGIT induces (CD3+) T cell dysfunction in colorectal cancer by inhibiting glucose metabolism. Front Immunol. 2021;12:688961.","journal-title":"Front Immunol"},{"issue":"1","key":"2638_CR113","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/jgh.15730","volume":"37","author":"S Li","year":"2022","unstructured":"Li S, Ding J, Wang Y, Wang X, Lv L. CD155\/TIGIT signaling regulates the effector function of tumor-infiltrating CD8\u2009+\u2009T cell by NF-\u03baB pathway in colorectal cancer. J Gastroenterol Hepatol. 2022;37(1):154\u201363.","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"2638_CR114","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1080\/08820139.2020.1758130","volume":"50","author":"X Zhou","year":"2021","unstructured":"Zhou X, Ding X, Li H, Yang C, Ma Z, Xu G, et al. Upregulation of TIGIT and PD-1 in colorectal cancer with mismatch-repair deficiency. Immunol Investig. 2021;50(4):338\u201355.","journal-title":"Immunol Investig"},{"issue":"7","key":"2638_CR115","doi-asserted-by":"publisher","first-page":"4514","DOI":"10.1111\/jcmm.14332","volume":"23","author":"B Ma","year":"2019","unstructured":"Ma B, Duan X, Zhou Q, Liu J, Yang X, Zhang D, et al. Use of aspirin in the prevention of colorectal cancer through TIGIT-CD155 pathway. J Cell Mol Med. 2019;23(7):4514\u201322.","journal-title":"J Cell Mol Med"},{"issue":"10","key":"2638_CR116","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.7150\/ijms.98343","volume":"21","author":"J Liu","year":"2024","unstructured":"Liu J, Zhou Q, Meng K, Yang X, Ma B, Su C, et al. Aspirin inhibits colorectal cancer via the TIGIT-BCL2-BAX pathway in T cells. Int J Med Sci. 2024;21(10):1990\u20139.","journal-title":"Int J Med Sci"},{"issue":"7","key":"2638_CR117","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1001\/jamaoncol.2020.1046","volume":"6","author":"F Petrelli","year":"2020","unstructured":"Petrelli F, Ghidini M, Ghidini A, Tomasello G. Outcomes following immune checkpoint inhibitor treatment of patients with microsatellite Instability-High cancers: A systematic review and Meta-analysis. JAMA Oncol. 2020;6(7):1068\u201371.","journal-title":"JAMA Oncol"},{"key":"2638_CR118","doi-asserted-by":"crossref","unstructured":"Vaddepally R, et al. Review of immune-related adverse events (irAEs) in non-small-cell lung cancer (NSCLC)-their incidence, management, multiorgan irAEs, and rechallenge. Biomedicines. 2022;10(4):790.","DOI":"10.3390\/biomedicines10040790"},{"key":"2638_CR119","doi-asserted-by":"publisher","unstructured":"Yousefi MJ, Rezvanimehr A, Saleki K, Mehrani A, Barootchi E, Ramezankhah M, et al. Inflammation-related MicroRNA alterations in epilepsy: a systematic review of human and animal studies. Rev Neurosci. 2025;36(8):901\u201323. https:\/\/doi.org\/10.1515\/revneuro-2025-0041. PMID: 40755381.","DOI":"10.1515\/revneuro-2025-0041"},{"issue":"1","key":"2638_CR120","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s12672-025-03234-3","volume":"16","author":"MJ Yousefi","year":"2025","unstructured":"Yousefi MJ, Afshar Y, Amoozadehsamakoosh A, Naseri A, Soltani F, Yazdanpanah N, et al. Interplay between innate-like T-cells and MicroRNAs in cancer immunity. Discover Oncol. 2025;16(1):1425.","journal-title":"Discover Oncol"},{"key":"2638_CR121","doi-asserted-by":"publisher","unstructured":"Saleki K, Xue M, Mazloomi A, Spencer-Dene B, Abdolrahman S. Nateri, \u03b2-catenin\/TCF4\/NANOG axis controls miR-302 transcription in colorectal cancer cells. Gene. 2025;977:149890. https:\/\/doi.org\/10.1016\/j.gene.2025.149890. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0378111925006808. ISSN 0378-1119.","DOI":"10.1016\/j.gene.2025.149890"},{"key":"2638_CR122","doi-asserted-by":"publisher","first-page":"113261","DOI":"10.1016\/j.intimp.2024.113261","volume":"143","author":"Y Wu","year":"2024","unstructured":"Wu Y, Xiao Y, Ding Y, Ran R, Wei K, Tao S, et al. Colorectal cancer cell-derived Exosomal miRNA-372-5p induces immune escape from colorectal cancer via PTEN\/AKT\/NF-\u03baB\/PD-L1 pathway. Int Immunopharmacol. 2024;143:113261.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"2638_CR123","first-page":"1","volume":"5","author":"S Louia","year":"2025","unstructured":"Louia S, Mosaddeghi-Heris R, Kamvar R, Zahmatkesh N, Damiri M, Esfahani MA, et al. Artificial intelligence in cancer genomics: transforming Diagnosis, Treatment, and precision medicine. Kindle. 2025;5(1):1\u2013234.","journal-title":"Kindle"},{"key":"2638_CR124","doi-asserted-by":"publisher","unstructured":"Zargar M, Khalilian S, Rasaei N, Saleki K, Jolfayi AG, Samieefar N, et al. Computational analysis of circRNA-related competing endogenous RNA networks in HIF-1 signaling of gastric cancer. Hum Gene. 2025;46:201458. https:\/\/doi.org\/10.1016\/j.humgen.2025.201458. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2773044125000841. ISSN 2773-0441.","DOI":"10.1016\/j.humgen.2025.201458"},{"key":"2638_CR125","doi-asserted-by":"publisher","unstructured":"Saleki K, Shaheen S, Xue M, Mazloomi A, Youssefi S, Kashfi H, et al. Disruption of NANOG-driven epithelial-mesenchymal transition (EMT) and self-renewal restores drug sensitivity in colorectal cancer. Drug Resist Updates. 2026;84:101321. https:\/\/doi.org\/10.1016\/j.drup.2025.101321. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1368764625001244. ISSN 1368-7646.","DOI":"10.1016\/j.drup.2025.101321"},{"issue":"2","key":"2638_CR126","doi-asserted-by":"publisher","first-page":"025017","DOI":"10.1088\/1361-6560\/aaf96c","volume":"64","author":"D Valentinuzzi","year":"2019","unstructured":"Valentinuzzi D, Simon\u010di\u010d U, Ur\u0161i\u010d K, Vrankar M, Turk M, Jeraj R. Predicting tumour response to anti-PD-1 immunotherapy with computational modelling. Phys Med Biol. 2019;64(2):025017.","journal-title":"Phys Med Biol"},{"issue":"6","key":"2638_CR127","doi-asserted-by":"publisher","first-page":"5908","DOI":"10.3390\/ijms24065908","volume":"24","author":"PS Sobral","year":"2023","unstructured":"Sobral PS, Luz VC, Almeida JM, Videira PA, Pereira F. Computational approaches drive developments in immune-oncology therapies for PD-1\/PD-L1 immune checkpoint inhibitors. Int J Mol Sci. 2023;24(6):5908.","journal-title":"Int J Mol Sci"},{"key":"2638_CR128","doi-asserted-by":"crossref","unstructured":"Saleki K, et al. Matrix metalloproteinase\/Fas ligand (MMP\/FasL) interaction dynamics in COVID-19: an in silico study and neuroimmune perspective. Heliyon. 2024;10(10):e30893.","DOI":"10.1016\/j.heliyon.2024.e30898"},{"issue":"5","key":"2638_CR129","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/JLB.6MA0721-376RR","volume":"112","author":"K Saleki","year":"2022","unstructured":"Saleki K, Mohamadi MH, Banazadeh M, Alijanizadeh P, Javanmehr N, Pourahmad R, et al. In Silico design of a TLR4-mediating multiepitope chimeric vaccine against amyotrophic lateral sclerosis via advanced immunoinformatics. J Leukoc Biol. 2022;112(5):1191\u2013207.","journal-title":"J Leukoc Biol"},{"key":"2638_CR130","doi-asserted-by":"crossref","unstructured":"Saleki K, Payandeh P, Shakeri M, Pourahmad R, Banazadeh M, Alijanizadeh P, et al. Utilizing immunoinformatics to target brain tumors; an aid to current neurosurgical practice. Interventional Pain Med Neuromodulation. 2022;2(1):e131144.","DOI":"10.5812\/ipmn-131144"},{"issue":"82","key":"2638_CR131","doi-asserted-by":"publisher","first-page":"111","DOI":"10.52547\/jmp.21.82.111","volume":"21","author":"R Latifi","year":"2022","unstructured":"Latifi R, Azadmehr A, Mosalla S, Saleki K, Hajiaghaee R. Scolicidal effects of the Nicotiana tabacum L. extract at various concentrations and exposure times. J Med Plants. 2022;21(82):111\u20138.","journal-title":"J Med Plants"},{"key":"2638_CR132","doi-asserted-by":"publisher","first-page":"153722","DOI":"10.1016\/j.phymed.2021.153722","volume":"91","author":"F Yan","year":"2021","unstructured":"Yan F, Wang X, Xie Y, Liu X, Yu L, Wang P, et al. Yangyin Fuzheng Jiedu prescription exerts anti-tumor immunity in hepatocellular carcinoma by alleviating exhausted T cells. Phytomedicine. 2021;91:153722.","journal-title":"Phytomedicine"},{"issue":"5","key":"2638_CR133","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1111\/cas.15311","volume":"113","author":"Y Xu","year":"2022","unstructured":"Xu Y, Wang H, Wang T, Chen C, Sun R, Yao W, et al. Dahuang Fuzi Baijiang Decoction restricts progenitor to terminally exhausted T cell differentiation in colorectal cancer. Cancer Sci. 2022;113(5):1739\u201351.","journal-title":"Cancer Sci"},{"issue":"2","key":"2638_CR134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41110-025-00359-x","volume":"50","author":"M Karimi","year":"2025","unstructured":"Karimi M, Javadi M, Hamzavi SF, Barootchi E, Kazemi K, Jahangiri S, et al. Effects of chokeberry products on cardiometabolic indices in adults: A GRADE-assessed systematic review and meta-analysis of RCTs. Nutrire. 2025;50(2):1\u201319.","journal-title":"Nutrire"},{"key":"2638_CR135","doi-asserted-by":"publisher","first-page":"115686","DOI":"10.1016\/j.biopha.2023.115686","volume":"168","author":"Z Vaziri","year":"2023","unstructured":"Vaziri Z, Saleki K, Aram C, Alijanizadeh P, Pourahmad R, Azadmehr A, et al. Empagliflozin treatment of cardiotoxicity: A comprehensive review of clinical, immunobiological, neuroimmune, and therapeutic implications. Biomed Pharmacother. 2023;168:115686.","journal-title":"Biomed Pharmacother"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-025-02638-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02638-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02638-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T01:02:52Z","timestamp":1770166972000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-025-02638-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":135,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2638"],"URL":"https:\/\/doi.org\/10.1186\/s12964-025-02638-6","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"5 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved the final version of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"81"}}